+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction

, : Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction. Clinical Cardiology 23(12): 877, December

Background: The antifibrinolytic effect of plasminogen-activator-inhibitor type 1 (PAI-1) may be responsible for delays in reperfusion and/or reinfarctions after streptokinase (STK) therapy in patients with acute myocardial infarction (AMI). Hypothesis: This study aimed to demonstrate the prognostic role of pretreatment PAI-1 levels for the outcome of STK therapy in patients with AMI, depending on reperfusion and/or reinfarction. Methods: The mean pretreatment PAI-1 level of 104 patients with AMI, treated with STK, determined by chromogenic method, was 5.8 +- 8.6 U/ml, range 0.3-66.2 U/ml. Streptokinase therapy was successful when reperfusion was achieved, as assessed noninvasively, without subsequent reinfarction; it failed when reperfusion was delayed and/or reinfarction developed. Results: Fibrinolysis with STK failed significantly in patients with elevated pretreatment PAI-1 levels (p < 0.05), especially with levels > 4.0 U/ml (p < 0.01). The mean pretreatment PAI-1 level was significantly higher in unsuccessfully treated patients. Multivariate statistical testing demonstrated that among pretreatment variables, elevated PAI-1 activity was the most significant independent risk factor of failed fibrinolysis with STK. Conclusions: Among pretreatment variables, elevated pretreatment PAI-1 activity in patients with AMI was the most significant independent risk factor of failed fibrinolysis with STK, especially at levels > 4.0 U/ml.


PMID: 10894435

DOI: 10.1002/clc.4960230723

Other references

Baillie, J.K., 2008: Simple, easily memorised "rules of thumb" for the rapid assessment of physiological compensation for respiratory acid-base disorders. Thorax 63(3): 289-290

Stern, R.S., 1989: Risk assessment of PUVA and cyclosporine. Lessons from the past; challenges for the future. Archives of Dermatology 125(4): 545-547

Osochuk, S.S., 2003: Comparative characteristics of changes in the fatty acid spectrum of high density lipoproteins in male patients of various age with appendicitis. The fatty acid spectrum, the content of cholesterol of total high-density lipoproteins (HDLP) and high-density lipoproteins3 as well as the activity of lecithin-cholesteryl-acyl-transferase (LCAT) were investigated in mature-age males (periods I a...

Green, H.N.; Wakefield, J.; Littlewood, G., 1957: The nature of cancer anaemia and its bearing on the immunological theory of cancer. British Medical Journal 2(5048): 779-784

King, K.L.; Winer, J.; Phillips, D.M.; Quach, J.; Williams, P.M.; Mather, J.P., 1998: Phenylephrine, endothelin, prostaglandin F2alpha' and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro. In these studies, we show that endothelin (ET), leukemia inhibitory factor (LIF), phenylephrine (PE), and prostaglandin F2alpha (PGF2alpha), which are all hypertrophic for neonatal rat cardiac myocytes in culture, induce distinct morphological, ph...

Klimanskiĭ, D.I., 1965: The influence of vago-sympathetic novocaine block on the function of the pancreas in combined treatment. Eksperimental'naia Khirurgiia i Anesteziologiia 10(3): 79-83

Magruder, G.B.; Guber, D., 1970: Fire prevention during surgery. Archives of Ophthalmology 84(2): 237-237

Prieto, M.E.; Sanhueza, P.; Kuhne, W.; Cohen, A.; Ruiz, P., 1969: Clinical experience in myxedematous coma. Revista Medica de Chile 97(4): 237-241

Galindo, N.; Osso, J.; Orti, M.; Conill, C.; Sainz de la Maza, T., 1978: Palm hyperhidrosis. 100 cases surgically treated by cervicodorsal sympathectomy. Angiologia 30(4): 131-133

Wiese, T.J.; Dunlap, J.A.; Yorek, M.A., 1997: Effect of L-fucose and D-glucose concentration on L-fucoprotein metabolism in human Hep G2 cells and changes in fucosyltransferase and alpha-L-fucosidase activity in liver of diabetic rats. L-Fucose is a monosaccharide that is present at low concentrations in serum and is a normal constituent of glycoproteins. In some pathological conditions, such as cancer, rheumatoid arthritis, and diabetes, there is an abnormal fucosylation of acu...